share_log

Keybanc Maintains Overweight on Avid Bioservices, Lowers Price Target to $14

Keybanc Maintains Overweight on Avid Bioservices, Lowers Price Target to $14

Keybanc维持对Avid Bioservices的增持,将目标股价下调至14美元
Benzinga ·  2023/12/08 04:22

Keybanc analyst Paul Knight maintains Avid Bioservices (NASDAQ:CDMO) with a Overweight and lowers the price target from $20 to $14.

Keybanc分析师保罗·奈特维持Avid Bioservices(纳斯达克股票代码:CDMO)增持 “增持”,并将目标股价从20美元下调至14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发